Rare disease specialist Amryt Pharma plans to expand its rare disease portfolio with the acquisition of troubled Aegerion Pharmaceuticals, a division of Canada’s Novelion. Aegerion holds US ...

UK-based specialist Amryt Pharma is looking to expand in 2018 after acquiring two rare disease treatments. A relative newcomer to the niche rare disease market, Amryt Pharma was founded by former ...

Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan ...

DUBLIN, Ireland, and Boston, MA, February 28, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and ...